Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifampicin effect on HSK31858 pharmacokinetics in healthy subjects
NCT07134478Phase 1Active, not recruiting
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Oct 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HSK31858, sponsored by Haisco Pharmaceutical Group Co., Ltd. Primary endpoints: Maximum Plasma Concentration at 96 hours and Area Under the Curve from Time Zero to Infinity at 96 hours. Started Oct 2024; status: active, not recruiting.
02
Drugs
HSK31858
Beyond the preview
Go deeper on NCT07134478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07134478.